Activity of ceftolozane-tazobactam and comparators when tested against bacterial surveillance isolates collected from patients at risk of infections caused by resistant gram-negative pathogens.
Diagn Microbiol Infect Dis
; 98(1): 115101, 2020 Sep.
Article
em En
| MEDLINE
| ID: mdl-32622289
Ceftolozane-tazobactam is an antipseudomonal cephalosporin combined with a ß-lactamase inhibitor. Ceftolozane-tazobactam has been approved for treatment of complicated urinary tract infections and acute pyelonephritis, for complicated intra-abdominal infections (with metronidazole) in adults, and for hospital-acquired bacterial pneumonia including ventilator-associated bacterial pneumonia. This study analyzed gram-negative pathogen susceptibility in US and European patients who are considered at risk for infections caused by pathogens resistant to commonly used antimicrobials: patients in the intensive care unit (ICU), patients on the hematology/oncology or transplant service who may be immunocompromised, and patients >65â¯years old (yo). ICU patients had the lowest susceptibility for Enterobacterales and PSA. The susceptibility for isolates from the immunocompromised andâ¯>65 yo groups was similar. Ceftolozane-tazobactam was the most active agent against PSA, with ≥90%S for >65 yo and immunocompromised, andâ¯>80%S for ICU. Meropenem and ceftolozane-tazobactam were the most active agents against Enterobacterales.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Métodos Terapêuticos e Terapias MTCI:
Plantas_medicinales
Assunto principal:
Pseudomonas aeruginosa
/
Infecções por Pseudomonas
/
Cefalosporinas
/
Enterobacteriaceae
/
Infecções por Enterobacteriaceae
/
Tazobactam
Tipo de estudo:
Etiology_studies
/
Risk_factors_studies
/
Screening_studies
Idioma:
En
Revista:
Diagn Microbiol Infect Dis
Ano de publicação:
2020
Tipo de documento:
Article
País de afiliação:
Estados Unidos